CTMX — CYTOMX THERAPEUTICS INC

Ownership history in PERCEPTIVE ADVISORS LLC · 25 quarters on record

This page tracks every 13F SEC filing in which PERCEPTIVE ADVISORS LLC reported a position in CYTOMX THERAPEUTICS INC (CTMX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

🏔 Peak position

1.76% (2018 Q1)

📊 Avg. % of fund

0.84%

📅 First filed

2015 Q4

📅 Last filed

2025 Q4

⏱ Quarters held

Position Intelligence

PERCEPTIVE ADVISORS LLC × CTMX AI Analytics

📉 PERCEPTIVE ADVISORS LLC underperformed the S&P 500 by –34.6% annually on this CTMX position. Timing score: 67% (12/18 decisions correct). Average cost basis: $7.66. Maximum drawdown during holding period: –92.0%.

📈 Position Alpha vs SPY

-34.6%

annualised excess return

❌ Significantly underperformed the S&P 500 by 34.6% ann.
24 quarters analyzed

⏱️ Timing Score

67%

✅ Decent timing — more right than wrong on entries and exits.
12 of 18 add/trim decisions correct

💰 Entry Quality

$7.66

-44.4% vs current ($4.26)

Best entry: $2.27 (2025 Q2) · Worst: $21.11 (2017 Q4)

🛡️ Drawdown Resilience

–92.0%

max drawdown while held

💪 Held through 2 major drawdowns (>20%).

💪 Fund Conviction

61%

buy-side decisions

11 adds · 7 trims. Bought during 6 of 13 down-price quarters. 📈 More buys than sells across the holding period.

📡 Position Trajectory

↑ Growing

last 4–5 quarters trend

📈 PERCEPTIVE ADVISORS LLC has been actively increasing its CTMX allocation — a bullish signal from insiders.
Currently 0.74% of portfolio

⚠ Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return × 4 (annualised). Not investment advice.

% of Fund (quarterly) CTMX price (monthly, adj. close)

📋 Quarterly Holdings History 10 quarters ▾

Quarter	Action	Shares	Change	Chg %	% of Fund	Mkt Value	Price (EOQ)
2025 Q4	UNCHANGED	9,680,185	—	0%	0.74%	$41.2M	$4.26
2025 Q3	ADDED	9,680,185	+2,686,539	+38.4%	0.89%	$30.9M	$3.19
2025 Q2	ADDED	6,993,646	+5,352,689	+326.2%	0.59%	$15.9M	$2.27
2021 Q2	REDUCED	1,640,957	-513,017	-23.8%	0.14%	$10.4M	$6.33
2021 Q1	REDUCED	2,153,974	-423,069	-16.4%	0.21%	$16.6M	$7.73
2020 Q4	UNCHANGED	2,577,043	—	0%	0.18%	$16.9M	$6.55
2020 Q3	UNCHANGED	2,577,043	—	0%	0.25%	$17.1M	$6.65
2020 Q2	REDUCED	2,577,043	-676,880	-20.8%	0.35%	$21.5M	$8.33
2020 Q1	UNCHANGED	3,253,923	—	0%	0.65%	$25.0M	$7.67
2019 Q4	UNCHANGED	3,253,923	—	0%	0.44%	$27.0M	$8.31

🏢 Other funds also holding CTMX

As of 2025 Q4 — sorted by position size

VR Adviser, LLC 3Y 3.27% Kynam Capital Management, LP 3Y 2.44% Commodore Capital LP 3Y 2.18% Exome Asset Management LLC 1.52% ADAR1 Capital Management, LLC 1.29% Ikarian Capital, LLC 3Y 1.06% Elmind Capital, LP 0.88% Vivo Capital, LLC 3Y 7Y 0.79% STEMPOINT CAPITAL LP 0.76% SCHULHOFF & CO INC 3Y 7Y 0.67%

← Back to PERCEPTIVE ADVISORS LLC Holdings

CTMX — CYTOMX THERAPEUTICS INC

Position Intelligence

🏢 Other funds also holding CTMX

Welcome to 13Foresight!